Abstract:Zika virus (ZIKV) is a mosquito-borne flavivirus that causes severe neurological disorders, such as microcephaly in fetuses. Most recently, an outbreak of ZIKV started in Brazil in 2015. To date, no therapeutic agents have been approved to treat ZIKV infection in the clinic. Here, we screened a small molecule inhibitor that can inhibit the function of ZIKV non-structural protein 2B (NS2B)-NS3 protease (ZIKV NS2B-NS3 protease), thereby interfering with viral replication and spread. First, we identified the half maximal inhibitory concentration (IC 50 ) of compound 3 (14.01 μM), 8 (6.85 μM), and 9 (14.2 μM) and confirmed that they are all non-competitive inhibitors. In addition, we have used the blind molecular docking method to simulate the inhibition area of three non-competitive inhibitors (compound 3, 8, and 9) with the ZIKV NS2B-NS3 protease. The results indicated that the four allosteric binding residues (Gln139, Trp148, Leu150, and Val220) could form hydrogen bonds or non-bonding interactions most frequently with the three compounds. The interaction might induce the reaction center conformation change of NS2B-NS3 protease to reduce catalyzed efficiency. The concentration of compounds required to reduce cell viability by 50% (CC 50 ), and the concentration of compounds required to inhibit virus-induced cytopathic effect by 50% (EC 50 ) of three potential compounds are >200 μM, 2.15 μM (compound 3), > 200 μM, 0.52 μM (compound 8) and 61.48 μM, 3.52 μM (compound 9), and Temoporfin are 61.05 μM, 2 μM, respectively. To select candidate compounds for further animal experiments, we analyzed the selectivity index (SI) of compound 3 (93.02), 8 (384.61), 9 (17.46), and Temoporfin (30.53, FDA-approved drug against cancer). Compound 8 has the highest SI value. Therefore, compound 8 was selected for verification in animal models. In vivo, compound 8 significantly delayed ZIKV-induced lethality and illness symptoms and decreased ZIKV-induced weight loss in a ZIKV-infected suckling mouse model. We conclude that compound 8 is worth further investigation for use as a potential future therapeutic agent against ZIKV infection.

A Peptide-Based Viral Inactivator Inhibits Zika Virus Infection in Pregnant Mice and Fetuses.

Cathelicidin-Derived Antimicrobial Peptides Inhibit Zika Virus Through Direct Inactivation and Interferon Pathway.

A Peptide-Based Virus Inactivator Protects Male Mice Against Zika Virus-Induced Damage of Testicular Tissue

Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice

A Single Injection of Human Neutralizing Antibody Protects Against Zika Virus Infection and Microcephaly in Developing Mouse Embryos.

Zika Virus Propagation and Release in Human Fetal Astrocytes Can Be Suppressed by Neutral Sphingomyelinase-2 Inhibitor GW4869

Sevsrvg Selectively Delivers Antiviral Sirna to Fetus Brain, Inhibits ZIKV Infection and Mitigates ZIKV-induced Microcephaly in Mouse Model

Inhibition of Na+/K+ ATPase blocks Zika virus infection in mice

Antiviral Activity of Peptide Inhibitors Derived from the Protein E Stem Against Japanese Encephalitis and Zika Viruses.

EVs Containing Host Restriction Factor IFITM3 Inhibited ZIKV Infection of Fetuses in Pregnant Mice Through Trans-placenta Delivery.

Erythromycin Estolate Inhibits Zika Virus Infection By Blocking Viral Entry As A Viral Inactivator

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets

A Biomimetic Nanodecoy Traps Zika Virus to Prevent Viral Infection and Fetal Microcephaly Development.

Zafirlukast, as a viral inactivator, potently inhibits infection of several flaviviruses, including Zika virus, dengue virus, and yellow fever virus

A vaccine inducing solely cytotoxic T lymphocytes fully prevents Zika virus infection and fetal damage

Elucidating the inhibitory mechanism of Zika virus NS2B-NS3 protease with dipeptide inhibitors: Insights from molecular docking and molecular dynamics simulations

Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication

Identification of desoxyrhapontigenin as a novel antiviral agent against congenital Zika virus infection

E90 subunit vaccine protects mice from Zika virus infection and microcephaly

Brevinin-2GHk, a Peptide Derived from the Skin of Fejervarya limnocharis, Inhibits Zika Virus Infection by Disrupting Viral Integrity

Chloroquine Inhibits Endosomal Viral RNA Release and Autophagy-Dependent Viral Replication and Effectively Prevents Maternal to Fetal Transmission of Zika Virus.